35 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
quantities of such Licensed Product, in particular, the production, the manufacture, the processing, the filling, the packaging, the labelling, the inspection … , component or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process
8-K
EX-1.1
KPRX
Kiora Pharmaceuticals Inc
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests
8-K
EX-1.1
ugwu12w 5fifi8052n
26 Jul 22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
4:31pm
8-K
EX-10.1
r439apit2et9oi
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
pxf1hpelvb7omx42i h4
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-99.1
asfke4u4et6 njpssnwk
14 Sep 20
Regulation FD Disclosure
6:50am
8-K
EX-99.1
ckbbu
1 Jun 20
Regulation FD Disclosure
6:55am
8-K
EX-10.1
1vjjeuwh
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
y4wwe1q
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am